Table 1.
Baseline characteristics of patients.
| Variable | All subjects (N = 240) | ESAs treatment |
P value | |
|---|---|---|---|---|
| Epiao® (n = 142) | Recormon® (n = 98) | |||
| Age, years | 57.85 ± 0.78 | 57.62 ± 0.94 | 58.47 ± 1.40 | 0.61 |
| Gender, female, n (%) | 92 (38.3) | 57 (40.1) | 35 (35.7) | 0.08 |
| Primary diseases, n (%) | 0.99 | |||
| Glomerular disease | 90 (37.5) | 52 (36.6) | 38 (38.8) | |
| Diabetes mellitus | 64 (26.7) | 38 (26.8) | 26 (26.5) | |
| Hypertension | 36 (15.0) | 21 (14.8) | 15 (15.3) | |
| Lupus nephritis | 10 (4.2) | 6 (4.2) | 4 (4.1) | |
| Autosomal dominant polycystic kidney disease | 9 (3.7) | 5 (3.5) | 4 (4.1) | |
| Gouty nephropathy | 8 (3.3) | 5 (3.5) | 3 (3.1) | |
| Vasculitis with renal damage | 5 (2.0) | 3 (2.1) | 2 (2.0) | |
| Obstructive nephropathy | 4 (1.7) | 3 (2.1) | 1 (1.0) | |
| Chronic transplant nephropathy | 4 (1.7) | 3 (2.1) | 1 (1.0) | |
| Malignant tumor-associated renal injury | 3 (1.3) | 2 (1.4) | 1 (1.0) | |
| Abercrombie degeneration | 2 (0.8) | 1 (0.7) | 1 (1.0) | |
| Unknown reasons | 5 (2.1) | 3 (2.1) | 2 (2.0) | |
| BUN (mmol/L) | 23.97 ± 0.44 | 23.9 ± 0.56 | 24.08 ± 0.69 | 0.84 |
| Scr (μmol/L) | 990.34 ± 21.02 | 997.42 ± 26.68 | 980.08 ± 34.12 | 0.69 |
| iPTH (pg/mL) | 451.65 ± 26.94 | 531.05 ± 39.57 | 336.66 ± 57.76 | <0.001 |
| Calcium (mmol/L) | 2.28 ± 0.01 | 2.29 ± 0.01 | 2.27 ± 0.47 | 0.47 |
| Phosphorus (mmol/L) | 2.01 ± 0.04 | 2.06 ± 0.04 | 1.94 ± 0.10 | 0.13 |
| Albumin (g/L) | 40.05 ± 0.27 | 40.2 ± 0.35 | 39.5 ± 0.44 | 0.51 |
| Ferritin (ng/mL) | 321.21 ± 14.62 | 298.84 ± 15.72 | 353.62 ± 27.4 | 0.08 |
| Transferrin saturation (%) | 31.74 ± 0.85 | 30.61 ± 1.12 | 33.38 ± 1.28 | 0.11 |
| Hemoglobin (g/L) | 103.15 ± 1.07 | 102.59 ± 1.38 | 103.54 ± 1.72 | 0.53 |
| Dry weight (kg) | 59.94 ± 0.60 | 59.05 ± 0.81 | 61.22 ± 0.86 | 0.07 |
| ESAs total dose (μ/week) | 5,781.25 ± 219.59 | 7,083.33 ± 264.93 | 3, 853.66 ± 225.13 | <0.001 |
| ESAs dose (μ/kg) | 100.25 ± 4.15 | 124.41 ± 5.67 | 65.25 ± 3.82 | <0.001 |
| ESAs price/week (US$) | 24.75 ± 1.34 | 12.99 ± 0.54 | 41.79 ± 2.26 | <0.001 |
Categorical variables are presented as percentages; continuous variables are presented as mean ± SEM. Demographic data and laboratory measurements among groups were compared by Pearson’s chi-squared test, Fisher’s exact-test, or Yate’s correction for continuity. The price of Epiao® (epoetin-alfa): US$5.5/3,000 μ; the price of Recormon® (epoetin-beta): US$21.5/2,000 μ.